MENU
+Compare
AUPH
Stock ticker: NASDAQ
AS OF
Apr 11 closing price
Price
$7.41
Change
+$0.07 (+0.95%)
Capitalization
1.02B

AUPH Aurinia Pharmaceuticals Forecast, Technical & Fundamental Analysis

Aurinia Pharmaceuticals Inc is a biopharmaceutical company... Show more

Industry: #Biotechnology
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for AUPH with price predictions
Apr 11, 2025

AUPH's Indicator enters downward trend

The Aroon Indicator for AUPH entered a downward trend on April 09, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 170 similar instances where the Aroon Indicator formed such a pattern. In of the 170 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on AUPH as a result. In of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for AUPH turned negative on March 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

AUPH moved below its 50-day moving average on April 03, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AUPH crossed bearishly below the 50-day moving average on April 08, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AUPH's RSI Oscillator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where AUPH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AUPH advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .

AUPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AUPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.696) is normal, around the industry mean (13.353). P/E Ratio (185.250) is within average values for comparable stocks, (63.023). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.756). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (4.606) is also within normal values, averaging (245.662).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

AUPH is expected to report earnings to rise 950.00% to 10 cents per share on May 01

Aurinia Pharmaceuticals AUPH Stock Earnings Reports
Q1'25
Est.
$0.10
Q4'24
Missed
by $0.02
Q3'24
Beat
by $0.08
Q2'24
Est.
$0.01
Q1'24
Beat
by $0.07
The last earnings report on February 27 showed earnings per share of 0 cents, missing the estimate of 2 cents. With 1.39M shares outstanding, the current market capitalization sits at 1.02B.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
14315 118 Avenue
Phone
+1 250 708-4272
Employees
300
Web
https://www.auriniapharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSIKX18.710.45
+2.46%
Goldman Sachs International Eq Inc Instl
TSFIX13.550.24
+1.80%
Touchstone Small Cap Institutional
VAFAX24.780.41
+1.68%
Invesco American Franchise A
PRCGX19.590.32
+1.66%
Perritt MicroCap Opportunities Investor
IWEDX12.360.14
+1.15%
Voya Large Cap Value W

AUPH and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AUPH has been loosely correlated with JSPR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AUPH jumps, then JSPR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUPH
1D Price
Change %
AUPH100%
+0.95%
JSPR - AUPH
44%
Loosely correlated
+12.13%
VCYT - AUPH
39%
Loosely correlated
+5.12%
CMRX - AUPH
37%
Loosely correlated
-0.12%
SCPH - AUPH
37%
Loosely correlated
+15.14%
GOSS - AUPH
37%
Loosely correlated
+6.18%
More